This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Neoprobe Corporation To Participate At Upcoming Investor Conferences

Neoprobe Corporation (NYSE Amex: NEOP) today announced that Dr. Mark Pykett, Neoprobe’s President and Chief Executive Officer will be participating in the following investor conferences over the coming weeks:
  • Deutsche Bank's 5 th Annual Med Tools Investor Forum, December 7-8, 2011 in Boston, Massachusetts. Management is scheduled to meet with institutional investors.
  • Oppenheimer & Co.’s 22nd Annual Healthcare Conference, December 13-14, 2011 in New York City. Management is invited to present an overview of the Company.
  • 2012 Biotech Showcase, January 9-11, 2012 in San Francisco. Management is invited to present an overview of the Company.

Dr. Pykett’s presentations will provide investors with a general business update regarding development activities currently underway as well as an overview of the Company’s growth strategy as it repositions itself as a precision diagnostics company focused on radiopharmaceuticals. A live webcast of presentations made at Oppenheimer & Co. and the Biotech Showcase conferences will be accessible through the Investors section of the company's website at Following each conference, the webcast will be archived for approximately 30 days.

About Neoprobe

Neoprobe Corporation (NYSE Amex: NEOP) is a biomedical company focused on enhancing oncology patient care and improving patient benefit through radiopharmaceutical product development. Neoprobe is actively developing two radiopharmaceutical agent platforms – Lymphoseek® and RIGScan™ CR – to help surgeons better identify and treat certain types of cancer. Neoprobe’s strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Company’s pipeline program through continued investment and selective acquisitions. For more information, please visit

Copyright Business Wire 2010

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community


Chart of I:DJI
DOW 16,102.38 -272.38 -1.66%
S&P 500 1,921.22 -29.91 -1.53%
NASDAQ 4,683.9190 -49.5780 -1.05%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs